{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Malignant Melanoma: Advances in Treatment
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Purpose of Activity
To provide an update of recent breakthroughs in the treatment of stage 4 melanomas.Learning Objectives
After completing this continuing education activity you will be able to:
- Identify the mitogen-activated protein kinase (MAPK) pathway and identify its importance.
- Recognize new therapies such as BRAF inhibitors and MEK inhibitors.
Disclosures
The authors and planners have disclosed no potential conflicts of interest, financial or otherwise.
Price:
$20.00
Credits:
- ANCC 2.3 CH
- DC - BON 2.3 CH
- KY-BON 2.0 CH
Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.--------------------------------------------------This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749. Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50-1223. Your certificate is valid in all states.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Test Code: JDNA0514A
Published: May/Jun 2014
Expires: 12/31/2026
Required Passing Score: 13/18 (72%)
Specialties:
Oncology